206. 脆弱Ｘ症候群 Fragile X syndrome Clinical trials / Disease details

臨床試験数 : 104 / 薬物数 : 87 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 79

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01555333 (ClinicalTrials.gov)	November 2011	1/3/2012	An Open Label Extension Study in Subjects With Fragile X Syndrome	An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject ...	Fragile X Syndrome	Drug: arbaclofen	Seaside Therapeutics, Inc.	NULL	Terminated	5 Years	50 Years	Both	357	Phase 3	United States
2	NCT01325220 (ClinicalTrials.gov)	June 2011	28/3/2011	Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children ...	A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolera ...	Fragile X Syndrome	Drug: arbaclofen;Drug: Placebo	Seaside Therapeutics, Inc.	NULL	Completed	5 Years	11 Years	Both	172	Phase 3	United States
3	NCT01282268 (ClinicalTrials.gov)	May 2011	20/1/2011	Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults Wit ...	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of ST ...	Fragile X Syndrome	Drug: arbaclofen;Drug: placebo	Seaside Therapeutics, Inc.	NULL	Completed	12 Years	50 Years	Both	125	Phase 3	United States
4	NCT01013480 (ClinicalTrials.gov)	November 2009	12/11/2009	An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome	An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in ...	Fragile X Syndrome	Drug: Arbaclofen	Seaside Therapeutics, Inc.	NULL	Terminated	6 Years	40 Years	Both	45	Phase 2	United States

First Previous1Next Last